2017
DOI: 10.17352/ojtm.000005
|View full text |Cite
|
Sign up to set email alerts
|

Leishmania antimony resistance/ susceptibility in Algerian foci

Abstract: 024-032. Medical Group AbstractAlgeria is one of the most endemic countries for cutaneous and visceral forms of leishmaniosis. Strikingly, with more than 21,000 annual cases of cutaneous leishmaniosis recorded in 2010, the disease has a major public health impact. For all forms of leishmaniosis, the fi rst line treatment relies on antimonial containing drug i.e., Glucantime®, developed during the 1950's. As early as 1986, antimonial treatment failure was reported during cutaneous leishmaniosis treatment. Linke… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 85 publications
(77 reference statements)
0
1
0
Order By: Relevance
“…In Tunisia and Algeria, L. major represents the causative agent of cutaneous leishmaniasis (CL) [32,33]. CL is a dynamic disease involving specific vectors, reservoirs, and host reservoirs.…”
Section: Discussionmentioning
confidence: 99%
“…In Tunisia and Algeria, L. major represents the causative agent of cutaneous leishmaniasis (CL) [32,33]. CL is a dynamic disease involving specific vectors, reservoirs, and host reservoirs.…”
Section: Discussionmentioning
confidence: 99%